The global Nucleic Acid-based Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid-based Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid-based Drugs.
Report Scope
The Nucleic Acid-based Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nucleic Acid-based Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nucleic Acid-based Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
Segment by Type
ASO
mRNA
siRNA
miRNA
saRNA
Aptamer
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nucleic Acid-based Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Nucleic Acid-based Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 ASO
1.2.3 mRNA
1.2.4 siRNA
1.2.5 miRNA
1.2.6 saRNA
1.2.7 Aptamer
1.3 Market by Application
1.3.1 Global Nucleic Acid-based Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nucleic Acid-based Drugs Market Perspective (2019-2030)
2.2 Nucleic Acid-based Drugs Growth Trends by Region
2.2.1 Global Nucleic Acid-based Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Nucleic Acid-based Drugs Historic Market Size by Region (2019-2024)
2.2.3 Nucleic Acid-based Drugs Forecasted Market Size by Region (2025-2030)
2.3 Nucleic Acid-based Drugs Market Dynamics
2.3.1 Nucleic Acid-based Drugs Industry Trends
2.3.2 Nucleic Acid-based Drugs Market Drivers
2.3.3 Nucleic Acid-based Drugs Market Challenges
2.3.4 Nucleic Acid-based Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nucleic Acid-based Drugs Players by Revenue
3.1.1 Global Top Nucleic Acid-based Drugs Players by Revenue (2019-2024)
3.1.2 Global Nucleic Acid-based Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Nucleic Acid-based Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nucleic Acid-based Drugs Revenue
3.4 Global Nucleic Acid-based Drugs Market Concentration Ratio
3.4.1 Global Nucleic Acid-based Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nucleic Acid-based Drugs Revenue in 2023
3.5 Nucleic Acid-based Drugs Key Players Head office and Area Served
3.6 Key Players Nucleic Acid-based Drugs Product Solution and Service
3.7 Date of Enter into Nucleic Acid-based Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Nucleic Acid-based Drugs Breakdown Data by Type
4.1 Global Nucleic Acid-based Drugs Historic Market Size by Type (2019-2024)
4.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Type (2025-2030)
5 Nucleic Acid-based Drugs Breakdown Data by Application
5.1 Global Nucleic Acid-based Drugs Historic Market Size by Application (2019-2024)
5.2 Global Nucleic Acid-based Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Nucleic Acid-based Drugs Market Size (2019-2030)
6.2 North America Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Nucleic Acid-based Drugs Market Size by Country (2019-2024)
6.4 North America Nucleic Acid-based Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nucleic Acid-based Drugs Market Size (2019-2030)
7.2 Europe Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Nucleic Acid-based Drugs Market Size by Country (2019-2024)
7.4 Europe Nucleic Acid-based Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nucleic Acid-based Drugs Market Size (2019-2030)
8.2 Asia-Pacific Nucleic Acid-based Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Nucleic Acid-based Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nucleic Acid-based Drugs Market Size (2019-2030)
9.2 Latin America Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Nucleic Acid-based Drugs Market Size by Country (2019-2024)
9.4 Latin America Nucleic Acid-based Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nucleic Acid-based Drugs Market Size (2019-2030)
10.2 Middle East & Africa Nucleic Acid-based Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Nucleic Acid-based Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Detail
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Nucleic Acid-based Drugs Introduction
11.2.4 Sarepta Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Detail
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Nucleic Acid-based Drugs Introduction
11.3.4 Nippon Shinyaku Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.3.5 Nippon Shinyaku Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech Nucleic Acid-based Drugs Introduction
11.4.4 BioNTech Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 Moderna Therapeutics
11.5.1 Moderna Therapeutics Company Detail
11.5.2 Moderna Therapeutics Business Overview
11.5.3 Moderna Therapeutics Nucleic Acid-based Drugs Introduction
11.5.4 Moderna Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.5.5 Moderna Therapeutics Recent Development
11.6 CureVac
11.6.1 CureVac Company Detail
11.6.2 CureVac Business Overview
11.6.3 CureVac Nucleic Acid-based Drugs Introduction
11.6.4 CureVac Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.6.5 CureVac Recent Development
11.7 Alnylam Pharmaceuticals
11.7.1 Alnylam Pharmaceuticals Company Detail
11.7.2 Alnylam Pharmaceuticals Business Overview
11.7.3 Alnylam Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.7.4 Alnylam Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.7.5 Alnylam Pharmaceuticals Recent Development
11.8 Regulus Therapeutics
11.8.1 Regulus Therapeutics Company Detail
11.8.2 Regulus Therapeutics Business Overview
11.8.3 Regulus Therapeutics Nucleic Acid-based Drugs Introduction
11.8.4 Regulus Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.8.5 Regulus Therapeutics Recent Development
11.9 Miragen Therapeutics
11.9.1 Miragen Therapeutics Company Detail
11.9.2 Miragen Therapeutics Business Overview
11.9.3 Miragen Therapeutics Nucleic Acid-based Drugs Introduction
11.9.4 Miragen Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.9.5 Miragen Therapeutics Recent Development
11.10 Mina Therapeutics
11.10.1 Mina Therapeutics Company Detail
11.10.2 Mina Therapeutics Business Overview
11.10.3 Mina Therapeutics Nucleic Acid-based Drugs Introduction
11.10.4 Mina Therapeutics Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.10.5 Mina Therapeutics Recent Development
11.11 NeXstar Pharmaceuticals
11.11.1 NeXstar Pharmaceuticals Company Detail
11.11.2 NeXstar Pharmaceuticals Business Overview
11.11.3 NeXstar Pharmaceuticals Nucleic Acid-based Drugs Introduction
11.11.4 NeXstar Pharmaceuticals Revenue in Nucleic Acid-based Drugs Business (2019-2024)
11.11.5 NeXstar Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
BioNTech
Moderna Therapeutics
CureVac
Alnylam Pharmaceuticals
Regulus Therapeutics
Miragen Therapeutics
Mina Therapeutics
NeXstar Pharmaceuticals
*If Applicable.